Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.

Sudipta RoyTimothy D WhiteheadShunqiang LiFoluso O AdemuyiwaRichard L WahlFarrokh DehdashtiKooresh I Shoghi

Published in: European journal of nuclear medicine and molecular imaging (2021)

We optimized robust FDG-PET radiomic signatures (RadSig) to predict and assess response to therapy in the context of a co-clinical imaging trial.

Keyphrases